What's Happening?
Proteolysis-targeting chimeras (PROTACs) are advancing from scientific breakthroughs to clinical modalities, but their development now faces new challenges. While PROTACs have shown potential in drug discovery by targeting previously 'undruggable' proteins,
the focus is shifting from merely demonstrating degradation potency to ensuring clinical and commercial viability. This involves integrating chemistry, pharmacology, safety, manufacturability, and clinical strategy early in the development process. The field is moving towards a more holistic approach, balancing degradation potency with developability and safety to translate promising degraders into viable medicines.
Why It's Important?
The maturation of PROTACs represents a significant shift in drug discovery, potentially expanding the range of therapeutic targets. This development could lead to more effective treatments for diseases that have been difficult to address with traditional inhibitors. However, the success of PROTACs depends on overcoming translational challenges, such as ensuring sufficient intracellular exposure and addressing safety concerns. The ability to integrate various aspects of drug development early on could lead to more efficient and successful clinical outcomes, benefiting patients and the pharmaceutical industry.
What's Next?
As PROTACs progress towards late-stage regulatory milestones, the focus will be on demonstrating their clinical and commercial viability. This includes developing translational assays and biomarkers to strengthen decision-making throughout preclinical and clinical development. The industry will need to adopt new development models that prioritize integration and balanced optimization across parameters. Successful translation of PROTACs into clinically viable therapies will require continued innovation and collaboration across various scientific disciplines.
